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Cardiovascular diseasesProfuse armamentariums are placed into the market after series
of clinical trials carried to ensure efﬁcacy and safety in Indian
population. New drug formulations and medical devices in the
cardiovascular diseases are approved by Drugs Controller
General (India) DCG(I) of Central Drugs Standard Control
Organization (CDSCO) as per the schedule Y of Drugs and
Cosmetics Act 1940 and Rules 1945 there under after the prior
demonstration of the drug's safety, efﬁcacy, and dose deﬁni-
tion.1 After the approval of new drug, it is mandatory to submit
Periodic Safety Update Reports (PSURs) to CDSCO every six
months for the ﬁrst two years and annually for the subsequent
two years.2
After the initial approval of the drug and its introduction in
the market, routine surveillance should is a norm for all the
prescribers as well as the concerned organization. During
clinical trials, the whole gamut of adverse drug reactions (ADRs)
may not be encountered due to paucity in the number of
population enrolled for the study. So, pharmacovigilance is
conﬁned mainly to detection of ADRs that were previously
either unknown or poorly understood. World Health Organiza-
tions (WHO) deﬁnes ‘‘Pharmacovigilance as the science and
activities relating to the detection, assessment, understanding
and prevention of adverse effects or any other drug-related
problem’’.3WHO established International Drug Monitoring in 1961 after
Thalidomide disaster. India launched its own ‘‘Pharmacovigi-
lance Program of India’’ (PvPI) with the vision to safeguard the
public health under Ministry of Health and Family Welfare,
Government of India in July 2010. Indian Pharmacopoeia
Commission (IPC) is functioning as National Coordination
Centre (NCC) for PvPI.4 At present, total 150 ADRs Monitoring
Centres (AMCs) are established under NCC-PvPI; all these AMCs
are either in medical colleges & hospitals, public health
programs, or corporate hospitals approved by Medical Council
of India that foster to collate, analyze, and submit the ADRs to
NCC.
Healthcare professionals can report ADRs associated with
cardiovascular drugs and related devices, whether known or
unknown, serious or non-serious, and frequent or rare by ﬁlling
the Suspected ADRs Reporting Form (Fig. 1) and submitted to
nearby AMC (available at www.ipc.gov.in).4 Also a helpline (1800
180 3024) is available to provide assistance in ADRs reporting.5
The accumulated information gathered through various
channels is put into the database, wherein they are analyzed
and assessed for safety update, and appropriate steps for
detection of signals and reducing the risks associated with the
drugs undertaken. The physician or anybody else who reports
will not have to face any legal action for reporting ADR and
patient information will be kept conﬁdential. After thoroughly
investigating the procured information in the form of evidence,
a recommendation could be made to national regulators, to
assess beneﬁt risk ratio, update prescribing information leaﬂet,
and promote rational use of medicines. The healthcare
professionals are obliged to report ADRs due to the use of
cardiovascular drugs and related devices for patient safety and
administration of quality care for the Indian population.
Fig. 1 – Suspected adverse drug reaction reporting form.
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